— Know what they know.
Not Investment Advice

ADMA NASDAQ

ADMA Biologics, Inc.
1W: -0.5% 1M: -22.7% 3M: -47.5% YTD: -52.7% 1Y: -58.6% 3Y: +107.3% 5Y: +391.9%
$8.24
-0.22 (-2.60%)
After Hours: $8.26 (+0.02, +0.24%)
Weekly Expected Move ±9.6%
$7 $7 $8 $9 $10
NASDAQ · Healthcare · Biotechnology · Alpha Radar Strong Sell · Power 34 · $1.9B mcap · 227M float · 3.20% daily turnover · Short 37% of daily vol

Cash Flow Trends

Operating Cash Flow
$50M -57.5% ▼
Capital Expenditures
$23M -163.3% ▼
5Y CAGR: +12.1%
Free Cash Flow
$28M -74.7% ▼
Dividends Paid
$0 +0.0% ▲
Buybacks
$32M +0.0% ▲
Net Change in Cash
-$16M -130.0% ▼

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2021FY2022FY2023FY2024FY2025
— Operating Activities —
Net Income-$72M-$66M-$28M$198M$147M
Depreciation & Amort.$5M$7M$8M$8M$8M
Stock-Based Comp.$3M$5M$6M$14M$20M
Change in Working Capital-$52M-$18M-$10M-$19M-$140M
Other Non-Cash Items$2M$12M$33M$2M$4M
Operating Cash Flow-$112M-$60M$9M$119M$50M
— Investing Activities —
Capital Expenditures-$14M-$14M-$5M-$8M-$23M
Acquisitions (Net)$0$0$0$0$1M
Investment Purchases$0$0$0$0$0
Investment Sales$0$0$0$0$0
Other Investing$0$0-$210K-$349K-$316K
Investing Cash Flow-$14M-$14M-$5M-$9M-$22M
— Financing Activities —
Net Debt Issuance-$34K$52M-$24M-$60M-$3M
Stock Repurchased$0$0-$1M$0-$32M
Dividends Paid$0$0$0$0$0
Other Financing-$62K-$8M-$14M-$6M-$12M
Financing Cash Flow$121M$109M-$39M-$58M-$44M
Net Change in Cash-$5M$35M-$35M$52M-$16M
Cash End of Period$51M$87M$51M$103M$88M
Free Cash Flow-$126M-$73M$4M$110M$28M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms